<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.2 20190208//EN" "JATS-archivearticle1-mathml3.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="review-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Int J Clin Pract</journal-id><journal-id journal-id-type="iso-abbrev">Int. J. Clin. Pract</journal-id><journal-id journal-id-type="doi">10.1111/(ISSN)1742-1241</journal-id><journal-id journal-id-type="publisher-id">IJCP</journal-id><journal-title-group><journal-title>International Journal of Clinical Practice</journal-title></journal-title-group><issn pub-type="ppub">1368-5031</issn><issn pub-type="epub">1742-1241</issn><publisher><publisher-name>John Wiley and Sons Inc.</publisher-name><publisher-loc>Hoboken</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">31313873</article-id><article-id pub-id-type="pmc">6790572</article-id><article-id pub-id-type="doi">10.1111/ijcp.13392</article-id><article-id pub-id-type="publisher-id">IJCP13392</article-id><article-categories><subj-group subj-group-type="overline"><subject>Systematic Review</subject></subj-group><subj-group subj-group-type="heading"><subject>Primary Care</subject></subj-group></article-categories><title-group><article-title>Point&#x02010;of&#x02010;care testing in primary care: A systematic review on implementation aspects addressed in test evaluations</article-title><alt-title alt-title-type="left-running-head">LINGERVELDER et al.</alt-title></title-group><contrib-group><contrib id="ijcp13392-cr-0001" contrib-type="author"><name><surname>Lingervelder</surname><given-names>Deon</given-names></name><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-6529-2564</contrib-id><xref ref-type="aff" rid="ijcp13392-aff-0001">
<sup>1</sup>
</xref></contrib><contrib id="ijcp13392-cr-0002" contrib-type="author"><name><surname>Koffijberg</surname><given-names>Hendrik</given-names></name><xref ref-type="aff" rid="ijcp13392-aff-0001">
<sup>1</sup>
</xref></contrib><contrib id="ijcp13392-cr-0003" contrib-type="author"><name><surname>Kusters</surname><given-names>Ron</given-names></name><xref ref-type="aff" rid="ijcp13392-aff-0001">
<sup>1</sup>
</xref><xref ref-type="aff" rid="ijcp13392-aff-0002">
<sup>2</sup>
</xref></contrib><contrib id="ijcp13392-cr-0004" contrib-type="author" corresp="yes"><name><surname>IJzerman</surname><given-names>Maarten J.</given-names></name><xref ref-type="aff" rid="ijcp13392-aff-0001">
<sup>1</sup>
</xref><xref ref-type="aff" rid="ijcp13392-aff-0003">
<sup>3</sup>
</xref><xref ref-type="aff" rid="ijcp13392-aff-0004">
<sup>4</sup>
</xref><address><email>m.j.ijzerman@utwente.nl</email></address></contrib></contrib-group><aff id="ijcp13392-aff-0001">
<label><sup>1</sup></label>
<named-content content-type="organisation-division">Health Technology and Services Research Department, Technical Medical Centre</named-content>
<institution>University of Twente</institution>
<city>Enschede</city>
<country country="NL">The Netherlands</country>
</aff><aff id="ijcp13392-aff-0002">
<label><sup>2</sup></label>
<named-content content-type="organisation-division">Laboratory for Clinical Chemistry and Haematology</named-content>
<institution>Jeroen Bosch Hospital</institution>
<city>Enschede</city>
<country country="NL">The Netherlands</country>
</aff><aff id="ijcp13392-aff-0003">
<label><sup>3</sup></label>
<named-content content-type="organisation-division">Cancer Health Services Research Unit, Faculty of Medicine, Dentistry and Health Sciences, School of Population and Global Health</named-content>
<institution>University of Melbourne</institution>
<city>Melbourne</city>
<named-content content-type="country-part">Vic.</named-content>
<country country="AU">Australia</country>
</aff><aff id="ijcp13392-aff-0004">
<label><sup>4</sup></label>
<institution>Victorian Comprehensive Cancer Centre</institution>
<city>Melbourne</city>
<named-content content-type="country-part">Vic.</named-content>
<country country="AU">Australia</country>
</aff><author-notes><corresp id="correspondenceTo"><label>*</label><bold>Correspondence</bold><break/>
Maarten J. IJzerman, Health Technology and Services Research Department, Technical Medical Centre, University of Twente, P.O. Box 217, Enschede, 7500 AE, The Netherlands.<break/>
Email: <email>m.j.ijzerman@utwente.nl</email><break/></corresp></author-notes><pub-date pub-type="epub"><day>19</day><month>8</month><year>2019</year></pub-date><pub-date pub-type="ppub"><month>10</month><year>2019</year></pub-date><volume>73</volume><issue>10</issue><issue-id pub-id-type="doi">10.1111/ijcp.v73.10</issue-id><elocation-id>e13392</elocation-id><history><date date-type="received"><day>15</day><month>1</month><year>2019</year></date><date date-type="rev-recd"><day>18</day><month>6</month><year>2019</year></date><date date-type="accepted"><day>09</day><month>7</month><year>2019</year></date></history><permissions><!--<copyright-statement content-type="issue-copyright"> Copyright &#x000a9; 2019 John Wiley & Sons Ltd <copyright-statement>--><copyright-statement content-type="article-copyright">&#x000a9; 2019 The Authors. <italic>International Journal of Clinical Practice</italic> published by John Wiley &#x00026; Sons Ltd</copyright-statement><license license-type="creativeCommonsBy-nc"><license-p>This is an open access article under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by-nc/4.0/">http://creativecommons.org/licenses/by-nc/4.0/</ext-link> License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="file:IJCP-73-e13392.pdf"/><abstract id="ijcp13392-abs-0001"><title>Abstract</title><sec id="ijcp13392-sec-0001"><title>Objectives</title><p>There are numerous point&#x02010;of&#x02010;care tests (POCTs) available on the market, but many of these are not used. This study reviewed literature pertaining to the evaluation/usage of POCTs in primary care, to investigate whether outcomes being reported reflect aspects previously demonstrated to be important for general practitioners (GPs) in the decision to implement a POCT in practice.</p></sec><sec id="ijcp13392-sec-0002"><title>Methods</title><p>Scopus and Medline were searched to identify studies that evaluated a POCT in primary care. We identified abstracts and full&#x02010;texts consisting of applied studies (eg trials, simulations, observational studies) and qualitative studies (eg interviews, surveys). Data were extracted from the included studies, such as the type of study, the extent to which manufacturers were involved in the study, and the biomarker/assay measured by the test(s). Studies were evaluated to summarise the extent to which they reported on, amongst others, clinical utility, user&#x02010;friendliness, turnaround&#x02010;time and technical performance (aspects previously identified as important).</p></sec><sec id="ijcp13392-sec-0003"><title>Results</title><p>The initial search resulted in 1398 publications, of which 125 met the inclusion criteria. From these studies, 83 POCTs across several disease areas (including cardiovascular disease, venous thromboembolism and respiratory&#x02010;tract&#x02010;infections) were identified. There was an inconsistency between what is reported in the studies and what GPs consider important. GPs perceive clinical utility as the most important aspect, yet this was rarely included explicitly in test evaluations in the literature, with only 8% of evaluations incorporating it in their analysis/discussion.</p></sec><sec id="ijcp13392-sec-0004"><title>Conclusions</title><p>This review showed that, despite the growing market and development of new POCTs, studies evaluating such tests fail to report on aspects that GPs find important. To ensure that an evaluation of a POCT is useful to primary care clinicians, future evaluations should not only focus on the technical performance aspects of a test, but also report on the aspects relating to the clinical utility and risks.</p></sec></abstract><counts><fig-count count="3"/><table-count count="6"/><page-count count="12"/><word-count count="6707"/></counts><custom-meta-group><custom-meta><meta-name>source-schema-version-number</meta-name><meta-value>2.0</meta-value></custom-meta><custom-meta><meta-name>cover-date</meta-name><meta-value>October 2019</meta-value></custom-meta><custom-meta><meta-name>details-of-publishers-convertor</meta-name><meta-value>Converter:WILEY_ML3GV2_TO_JATSPMC version:5.8.0 mode:remove_FC converted:16.04.2020</meta-value></custom-meta></custom-meta-group></article-meta><notes><p content-type="self-citation">
<mixed-citation publication-type="journal" id="ijcp13392-cit-1001">
<string-name>
<surname>Lingervelder</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Koffijberg</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Kusters</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>IJzerman</surname>
<given-names>MJ</given-names>
</string-name>. <article-title>Point&#x02010;of&#x02010;care testing in primary care: A systematic review on implementation aspects addressed in test evaluations</article-title>. <source xml:lang="en">Int J Clin Pract</source>. <year>2019</year>;<volume>73</volume>:<elocation-id>e13392</elocation-id>
<pub-id pub-id-type="doi">10.1111/ijcp.13392</pub-id>
<pub-id pub-id-type="pmid">31313873</pub-id></mixed-citation>
</p></notes></front><body id="ijcp13392-body-0001"><p>
<boxed-text position="anchor" content-type="box" id="ijcp13392-blkfxd-0001" orientation="portrait"><sec id="ijcp13392-sec-0006"><title>Review criteria</title><p>
<list list-type="bullet" id="ijcp13392-list-0001"><list-item><p>Searches were performed on Scopus and Medline for applied studies that evaluated a point&#x02010;of&#x02010;care test in primary care regarding its effectiveness, performance, usage or application. Studies had to focus on a specific point&#x02010;of&#x02010;care diagnostic being applied in a high&#x02010;income country. During the full&#x02010;text assessment, each test evaluation was assessed to summarise the extent to which predefined determinants were being reported on.</p></list-item></list>
</p></sec><sec id="ijcp13392-sec-0007"><title>Message for the clinic</title><p>
<list list-type="bullet" id="ijcp13392-list-0002"><list-item><p>There remains a gap between the aspects being addressed in point&#x02010;of&#x02010;care test evaluations and the aspects that clinicians find important. Clinicians should aim to collaborate and take part in test evaluations, to ensure that all the aspects that are essential to support their decision making in implementing such tests are covered during the evaluation process.</p></list-item></list>
</p></sec></boxed-text>
</p><sec id="ijcp13392-sec-0008"><label>1</label><title>INTRODUCTION</title><p>Diagnostic testing plays a vital part in primary healthcare, providing valuable insight to support decisions regarding treatment and referral to secondary care.<xref rid="ijcp13392-bib-0001" ref-type="ref">1</xref> Patient outcomes can be greatly improved with diagnostic testing when it is used to exclude a disease and identify those patients that will benefit the most from downstream actions, such as initiating, modifying, stopping or withholding treatment.<xref rid="ijcp13392-bib-0002" ref-type="ref">2</xref> In primary care, the diagnostic process traditionally relies on laboratory testing. Laboratory information must therefore be accurate, reliable and reproducible. Although in some diagnostic questions rapid delivery of the test results is important, traditional centralised laboratories tend to highlight the quality and reliability of tests above the turn&#x02010;around&#x02010;time.<xref rid="ijcp13392-bib-0003" ref-type="ref">3</xref> For many diseases, care providers and patients increasingly expect patient&#x02010;focused, specialised diagnostic tests that can be performed quickly, easily and provide results within minutes.<xref rid="ijcp13392-bib-0004" ref-type="ref">4</xref> This has led to the development of easy&#x02010;to&#x02010;use analysers that can be performed at the point of care, more commonly known as point&#x02010;of&#x02010;care (POC) testing or near&#x02010;patient testing.<xref rid="ijcp13392-bib-0001" ref-type="ref">1</xref>
</p><p>The reason for implementing a POCT will vary according to the setting. In emergency departments or intensive care units, POCTs are used to find test results immediately to help guide life&#x02010;saving decisions. In resource&#x02010;limited settings, access to healthcare facilities is typically limited. In such settings, POCTs are beneficial in terms of their ease of use independent from the physical presence of a laboratory.<xref rid="ijcp13392-bib-0005" ref-type="ref">5</xref> In primary care settings, POCTs are typically used to prevent unnecessary referrals to specialised or secondary care, to guide diagnostic and treatment decisions, and to provide reassurance to patients, for example by excluding an illness. The rapid analysis can also lead to improved clinical performance, since it eliminates the potentially long intervals between the patient's initial examination and the discussion of the test results.<xref rid="ijcp13392-bib-0004" ref-type="ref">4</xref>
</p><p>The first major systematic review of POCTs in primary care was published more than 20&#x000a0;years ago by Hobbs et al,<xref rid="ijcp13392-bib-0006" ref-type="ref">6</xref> who concluded that evidence in support of the general introduction of POCTs in general practice was low. Since then, the POC diagnostic market has grown substantially and continues to do so because of the increasing development of new (supporting) technologies such as novel biomarkers, wireless connectivity, nanoparticle techniques and information sharing capabilities.<xref rid="ijcp13392-bib-0007" ref-type="ref">7</xref> It is expected that the global POC diagnostics market will reach $40.50 billion by 2022.<xref rid="ijcp13392-bib-0008" ref-type="ref">8</xref> Despite this growing market, primary care clinicians generally are hesitant to implement POCTs in their practice. According to a study on POC blood tests by Jones et al,<xref rid="ijcp13392-bib-0009" ref-type="ref">9</xref> this is mainly because of concerns about accuracy, over&#x02010;reliance on tests and limited usefulness.</p><p>A recent survey of general practitioners (GPs) in the UK,<xref rid="ijcp13392-bib-0010" ref-type="ref">10</xref> identified several themes regarding what GPs perceive as facilitators and barriers to the implementation of a POCT. Some of these themes were the workload, clinical utility, patient satisfaction, reimbursement, legislations, technical performance, connectivity, training and maintenance. A similar survey study in the Netherlands found comparable results, with Dutch GPs believing the proven effect on clinical management and the tests&#x02019; reliability to be among the most important aspects of POCTs.<xref rid="ijcp13392-bib-0011" ref-type="ref">11</xref> This study aims to systematically review recent literature pertaining to the evaluation and usage of POCTs in primary care and to investigate whether the outcomes and evidence reported in the literature, reflect previously established factors<xref rid="ijcp13392-bib-0012" ref-type="ref">12</xref> that are important for GPs in the decision to implement a POCT.</p></sec><sec sec-type="materials-and-methods" id="ijcp13392-sec-0009"><label>2</label><title>MATERIALS AND METHODS</title><sec id="ijcp13392-sec-0010"><label>2.1</label><title>Literature search</title><p>The PRISMA guidelines were followed while carrying out this systematic review of available POCTs for primary care. Since this review aims to identify any POCTs that can be implemented in primary care, all types of primary research studies were included in the initial search. For this reason, it was not required that any specific outcome measure was reported in the initial search and no specific study characteristics or PICO&#x02010;statement was used as part of the inclusion criteria. The review protocol for this systematic review is provided in Appendix <xref rid="ijcp13392-app-0001" ref-type="app">A</xref> as a series of steps that were followed.</p><p>Two databases (Scopus and Medline) were searched for relevant English or Dutch publications between 2007 and 2017. The initial search was performed in September 2017. The search included all terms and text words related to the intervention (POC diagnostics) and the setting (Primary Care). The search query used was (Scopus format):</p><p>TITLE&#x02010;ABS&#x02010;KEY ("POCT"&#x000a0;OR&#x000a0;"Point of care"&#x000a0;OR&#x000a0;"Point of care testing" OR "rapid testing" OR "bedside testing" OR "laboratory&#x02010;independent"&#x000a0;OR&#x000a0;"near patient testing")&#x000a0;AND TITLE&#x02010;ABS&#x02010;KEY (diagnos*)&#x000a0;AND ALL ("Primary Care"&#x000a0;OR&#x000a0;"General Pract*" OR "GP"&#x000a0;OR "Primary Healthcare"&#x000a0;OR&#x000a0;"Primary Health Care").</p></sec><sec id="ijcp13392-sec-0011"><label>2.2</label><title>Study selection</title><p>Only publications that met the following inclusion criteria were selected for the review:
<list list-type="order" id="ijcp13392-list-0003"><list-item><p>Publications should focus on POC diagnostic technologies only. Publications reporting on, for example scorecards or methodologies to diagnose patients at the point of care, decision support tools or online (cloud) systems, results sharing, electronic health records, etc were excluded.</p></list-item><list-item><p>Publications should focus on specific POC diagnostic technologies and not only provide a general summary of POCTs.</p></list-item><list-item><p>Publications should focus on primary care only. Publications focusing on secondary care or self&#x02010;monitoring were excluded.</p></list-item><list-item><p>Publications should focus on high&#x02010;income countries only. Publications that explicitly stated that their focus is on remote or rural areas were excluded, even if within a developed country.</p></list-item><list-item><p>Publications should be an applied study that evaluates a POCT in terms of its effectiveness, performance, usage or application. This includes qualitative studies (such as surveys and interviews) and modelling studies. Reviews were excluded.</p></list-item></list>
</p><p>After removing duplicate publications from the initial search results, the abstracts were screened to determine whether publications met the inclusion criteria. Publications that undoubtedly failed to meet all of the inclusion criteria, based on the abstract screening, were excluded from the full&#x02010;text assessment. If there was any doubt on whether or not a publication met the inclusion criteria, it was included for full&#x02010;text assessment. The abstract screening was performed by one reviewer (DL), and potential issues were discussed with a second reviewer (HK) when required. The full&#x02010;text assessment of all included publications was performed by one reviewer (DL).</p></sec><sec id="ijcp13392-sec-0012"><label>2.3</label><title>Data extraction and management</title><p>The data were extracted manually by one reviewer (DL) from the studies into Microsoft Excel (version 2016) in predefined and labelled columns. The following information was extracted from each of the included publications:
<list list-type="order" id="ijcp13392-list-0004"><list-item><p>The study design, classified according to one of three categories; namely, empirical study (trials, cohort studies, etc), qualitative study (interviews, surveys, etc) or modelling study.</p></list-item><list-item><p>If relevant, the country where the study was performed. For multi&#x02010;country studies, each individual country was counted separately.</p></list-item><list-item><p>If applicable, the role that the manufacturer played in the study. This was classified in one of seven categories; namely, (a) manufacturer provided some financial support to the study, (b) manufacturer funded the study, (c) manufacturer provided the analyser/test, (d) manufacturer funded the study and provided the analyser/test, (e) one or more authors are employed by the manufacturer, (f) manufacturer played no part in the study or (g) nothing specified about funding or manufacturer involvement.</p></list-item><list-item><p>The name of the POC device/test that was evaluated.</p></list-item><list-item><p>The biomarker/assay that was measured by the POCT.</p></list-item></list>
</p><p>If a study evaluated more than one POCT, a separate data entry (row) was added for each individual test evaluation. During the full&#x02010;text assessment, each test evaluation study was assessed to summarise the extent to which predefined determinants were being reported on. These determinants were identified previously<xref rid="ijcp13392-bib-0012" ref-type="ref">12</xref> as key factors that affect the decision to implement a POCT in primary care. All 20 of these determinants are listed in Table <xref rid="ijcp13392-tbl-0001" ref-type="table">1</xref>.</p><table-wrap id="ijcp13392-tbl-0001" xml:lang="en" orientation="portrait" position="float"><label>Table 1</label><caption><p>List of determinants and their description (Reproduced from Kip et al <xref rid="ijcp13392-bib-0012" ref-type="ref">12</xref>)</p></caption><table frame="hsides" rules="groups"><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><thead valign="top"><tr style="border-bottom:solid 1px #000000"><th align="left" valign="top" rowspan="1" colspan="1">&#x000a0;</th><th align="left" valign="top" rowspan="1" colspan="1">Determinant</th><th align="left" valign="top" rowspan="1" colspan="1">Description</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">1</td><td align="left" rowspan="1" colspan="1">Satisfaction patient</td><td align="left" rowspan="1" colspan="1">Extent to which the use of the POC test is expected to improve service for the patient.</td></tr><tr><td align="left" rowspan="1" colspan="1">2</td><td align="left" rowspan="1" colspan="1">Clarity of procedure</td><td align="left" rowspan="1" colspan="1">Extent to which the procedures for using the POC test are clearly described in protocols and/or manuals.</td></tr><tr><td align="left" rowspan="1" colspan="1">3</td><td align="left" rowspan="1" colspan="1">User&#x02010;friendliness</td><td align="left" rowspan="1" colspan="1">Extent to which the POC test is easy to perform by the layman.</td></tr><tr><td align="left" rowspan="1" colspan="1">4</td><td align="left" rowspan="1" colspan="1">Test interpretation</td><td align="left" rowspan="1" colspan="1">Extent to which the POC test result is easy to read and the various test results are easy to interpret.</td></tr><tr><td align="left" rowspan="1" colspan="1">5</td><td align="left" rowspan="1" colspan="1">Turn&#x02010;around&#x02010;time (TAT)</td><td align="left" rowspan="1" colspan="1">Extent to which the POC test results are instantly available.</td></tr><tr><td align="left" rowspan="1" colspan="1">6</td><td align="left" rowspan="1" colspan="1">Frequency of use</td><td align="left" rowspan="1" colspan="1">Extent to which the test is used sufficiently with respect to the indication and the size of the general practice.</td></tr><tr><td align="left" rowspan="1" colspan="1">7</td><td align="left" rowspan="1" colspan="1">Room for innovation</td><td align="left" rowspan="1" colspan="1">The extent to which the pressure of daily practice leaves room for innovation and a mind&#x02010;set for change.</td></tr><tr><td align="left" rowspan="1" colspan="1">8</td><td align="left" rowspan="1" colspan="1">Workload</td><td align="left" rowspan="1" colspan="1">Extent to which the POC test can be implemented without dramatic changes in the current way of working and user's workload.</td></tr><tr><td align="left" rowspan="1" colspan="1">9</td><td align="left" rowspan="1" colspan="1">Support, training and quality control</td><td align="left" rowspan="1" colspan="1">Extent to which the introduction, maintenance and quality control of the POC test, as well as the training of personnel is sufficient and supported by a coordinator from the laboratory, manufacturer and general practice.</td></tr><tr><td align="left" rowspan="1" colspan="1">10</td><td align="left" rowspan="1" colspan="1">Connectivity</td><td align="left" rowspan="1" colspan="1">Extent to which the POC test results and errors are registered in an information system (HIS)</td></tr><tr><td align="left" rowspan="1" colspan="1">11</td><td align="left" rowspan="1" colspan="1">Clinical utility</td><td align="left" rowspan="1" colspan="1">Extent to which a correct (treatment) decision, as based on the point&#x02010;of&#x02010;care (POC) test result, has added value in clinical outcomes.</td></tr><tr><td align="left" rowspan="1" colspan="1">12</td><td align="left" rowspan="1" colspan="1">Technical performance</td><td align="left" rowspan="1" colspan="1">The extent to which the POC test is exact, precise, reliable and robust in the hands of the user.</td></tr><tr><td align="left" rowspan="1" colspan="1">13</td><td align="left" rowspan="1" colspan="1">Negative Predictive Value</td><td align="left" rowspan="1" colspan="1">Negative predictive value: Proportion of negative results that are true negative, which enhances the user's ability to reliably rule out a condition.</td></tr><tr><td align="left" rowspan="1" colspan="1">14</td><td align="left" rowspan="1" colspan="1">Positive Predictive Value</td><td align="left" rowspan="1" colspan="1">Positive predictive value: Proportion of positive results that are true positive, which enhances the user's ability to reliably diagnose a condition.</td></tr><tr><td align="left" rowspan="1" colspan="1">15</td><td align="left" rowspan="1" colspan="1">Risks</td><td align="left" rowspan="1" colspan="1">The impact of a (wrong) treatment/advice based on a (wrong) test result.</td></tr><tr><td align="left" rowspan="1" colspan="1">16</td><td align="left" rowspan="1" colspan="1">Clinical guidelines</td><td align="left" rowspan="1" colspan="1">Extent to which the POC test is implemented in national guidelines.</td></tr><tr><td align="left" rowspan="1" colspan="1">17</td><td align="left" rowspan="1" colspan="1">Scientific evidence</td><td align="left" rowspan="1" colspan="1">Extent to which the added value of the POC test is demonstrated (as compared with current practice) in scientific literature, in the right patient population and for a specific clinical pathway.</td></tr><tr><td align="left" rowspan="1" colspan="1">18</td><td align="left" rowspan="1" colspan="1">Reimbursement</td><td align="left" rowspan="1" colspan="1">Is the POC test reimbursed for the general practitioner?</td></tr><tr><td align="left" rowspan="1" colspan="1">19</td><td align="left" rowspan="1" colspan="1">Overall costs</td><td align="left" rowspan="1" colspan="1">Extent to which the POC test is expected to decrease costs of the healthcare system.</td></tr><tr><td align="left" rowspan="1" colspan="1">20</td><td align="left" rowspan="1" colspan="1">Legislations</td><td align="left" rowspan="1" colspan="1">Extent to which the innovation fits into existing legislations.</td></tr></tbody></table><permissions><copyright-holder>John Wiley &#x00026; Sons, Ltd</copyright-holder><license><license-p>This article is being made freely available through PubMed Central as part of the COVID-19 public health emergency response. It can be used for unrestricted research re-use and analysis in any form or by any means with acknowledgement of the original source, for the duration of the public health emergency.</license-p></license></permissions></table-wrap><p>Some of these determinants are not applicable to a POCT specifically, but rather to the disease prevalence and the GP and his practice (Frequency of use, Room for innovation, Risks). For example Frequency of use and Room for innovation are both determinants that are associated directly with the GP&#x02019;s practice, while the impact and Risks of tests would differ between diseases. It is expected that these determinants will not be reported in the evaluations as frequently as some of the others. If there was any uncertainty to the first reviewer (DL) about whether a publication discussed a certain determinant, it was examined by a second reviewer (HK). On occasions when these two reviewers could not agree on a decision, a third reviewer was involved in making a final decision (either RK or MJIJ).</p><p>The data extracted from the included publications were summarised in both text and table format, before providing a descriptive synthesis of findings. Results were divided according to the biomarker/assay that the test measures.</p></sec></sec><sec sec-type="results" id="ijcp13392-sec-0013"><label>3</label><title>RESULTS</title><sec id="ijcp13392-sec-0014"><label>3.1</label><title>Search results</title><p>A total of 1398 studies were obtained from the initial search of the Medline and Scopus database. To ensure that the search resulted in a comprehensive set of relevant publications, the selected search query was broad. This did, however, result in a large number of publications being excluded during the abstract screening, mostly because of publications focusing on something other than a (specific) POC diagnostic. After a screening of all abstracts, 286 studies were included in the full&#x02010;text assessment.</p><p>After the full&#x02010;text assessment, 125 studies were included in the final review. Studies were mostly excluded based on full&#x02010;text assessment because they did not focus on POC diagnostics (n&#x000a0;=&#x000a0;81), but instead described a tool, strategy or guideline to support POC testing. The PRISMA flow diagram of the search is presented in Appendix <xref rid="ijcp13392-app-0001" ref-type="app">A</xref>.</p></sec><sec id="ijcp13392-sec-0015"><label>3.2</label><title>Characteristics of included publications</title><p>The 125 included studies consisted of 112 applied studies, 7 qualitative studies, 5 simulation studies and 1 study that used both applied and qualitative methods. The majority of the studies were applied in The Netherlands (n&#x000a0;=&#x000a0;25; 20.0%), US (n&#x000a0;=&#x000a0;17; 13.6%) and UK (n&#x000a0;=&#x000a0;13; 10.4%), followed by Spain (n&#x000a0;=&#x000a0;6; 4.8%), Finland (n&#x000a0;=&#x000a0;6; 4.8%), Australia (n&#x000a0;=&#x000a0;5; 4%) and Canada (n&#x000a0;=&#x000a0;5; 4%). In 35 studies (28%), the manufacturer(s) of the test(s) being evaluated provided support by either funding the study in full (n&#x000a0;=&#x000a0;10) or partially (n&#x000a0;=&#x000a0;8), by providing the analyser(s)/test(s) (n&#x000a0;=&#x000a0;14), or by both funding the study and providing the analyser(s)/test(s) (n&#x000a0;=&#x000a0;3). There was a single study where one of the authors was an employee of the manufacturer. For the majority of studies (n&#x000a0;=&#x000a0;62; 49.6%) the manufacturer(s) had no involvement, whereas in 24 (19.2%) of the studies nothing was specified about funding or manufacturer involvement.</p></sec><sec id="ijcp13392-sec-0016"><label>3.3</label><title>Overall results</title><p>From the 125 studies in the synthesis set, 195 test evaluations were identified. The percentage that each determinant was reported in the test evaluations are provided in Figure <xref rid="ijcp13392-fig-0001" ref-type="fig">1</xref>, together with the overall weight of each determinant as found by.<xref rid="ijcp13392-bib-0012" ref-type="ref">12</xref> The four determinants that were reported the most were turn&#x02010;around&#x02010;time (n&#x000a0;=&#x000a0;105; 52.2%), technical performance (n&#x000a0;=&#x000a0;97; 48.3%), positive predictive value (n&#x000a0;=&#x000a0;91; 45.3%) and negative predictive value (n&#x000a0;=&#x000a0;89; 44.3%). The determinants reported the least in the evaluations were room for innovation (n&#x000a0;=&#x000a0;0; 0%) and risks (n&#x000a0;=&#x000a0;1; 0.5%), followed by reimbursement (n&#x000a0;=&#x000a0;2; 1.0%), legislations (n&#x000a0;=&#x000a0;3; 1.5%) and scientific evidence (n&#x000a0;=&#x000a0;3; 1.5%).</p><fig fig-type="Figure" xml:lang="en" id="ijcp13392-fig-0001" orientation="portrait" position="float"><label>Figure 1</label><caption><p>Comparison of determinant weights according to GPs and the percentage of times that each determinant was reported in the literature</p></caption><graphic id="nlm-graphic-1" xlink:href="IJCP-73-e13392-g001"/></fig></sec><sec id="ijcp13392-sec-0017"><label>3.4</label><title>POCTs per measurement</title><p>In 20 of the 195 evaluations (10.26%), the exact test(s) could not be recognised, since no identifiable information (such as the name of the device or the manufacturer) were provided. There were also 12 POCTs, occurring in 24 test evaluations, of which no information could be found on the official manufacturer or partner websites. It is expected that these tests are either discontinued/recalled (such as the Clearview Simplify D&#x02010;Dimer device) or that the names of these tests have been changed. In cases where it could be confirmed that a device name has been changed (eg the DCA 2000 has been renamed the DCA Vantage) the evaluations were included and categorised under the new device name. If no confirmation could be found, the device was excluded from the final list of tests. After excluding the above&#x02010;mentioned 20&#x000a0;+&#x000a0;24&#x000a0;=&#x000a0;44 evaluations, a total of 83 POCTs were identified with a total of 151 test evaluations. Each of these POCTs has at least one test evaluation. The most frequently evaluated tests were those measuring HbA1c (n&#x000a0;=&#x000a0;14; 16.9%), CRP (n&#x000a0;=&#x000a0;6; 7.2%), D&#x02010;Dimer (n&#x000a0;=&#x000a0;6; 7.2%) and Influenza and/or RSV (n&#x000a0;=&#x000a0;6; 7.2%).</p><sec id="ijcp13392-sec-0018"><label>3.4.1</label><title>Haemoglobin A1c</title><p>A haemoglobin A1c (HbA1c) test measures glycated haemoglobin that gives an indication of the average blood glucose level of the past 60&#x02010;120&#x000a0;days. Seeing as the prevalence of diabetes continues to rise each year, the timely management of HbA1c is particularly important in the primary care pathways of both patients with diabetes and those that remained undiagnosed.<xref rid="ijcp13392-bib-0013" ref-type="ref">13</xref> In Appendix <xref rid="ijcp13392-app-0002" ref-type="app">B</xref>, Table <xref rid="ijcp13392-tbl-0002" ref-type="table">B1</xref>, a list of the 14 HbA1c POCTs that were identified during the review is provided, in no particular order. The three most evaluated tests were the DCA Vantage Analyzer (n&#x000a0;=&#x000a0;8), the Alere Afininion AS100 Analyzer (n&#x000a0;=&#x000a0;6) and the A1CNow system (n&#x000a0;=&#x000a0;5).</p></sec><sec id="ijcp13392-sec-0019"><label>3.4.2</label><title>C&#x02010;reactive protein</title><p>C&#x02010;reactive protein (CRP) is an acute phase protein produced by the liver when inflammation occurs. Measuring CRP levels can help identify patients that are at high risk of having respiratory tract infections, inflammatory diseases or cardiovascular disease. To support the early detection of serious infections and diseases, CRP testing is increasingly being introduced in primary care.<xref rid="ijcp13392-bib-0014" ref-type="ref">14</xref> A list of the 8 CRP POCTs that were identified during the review is provided in Appendix <xref rid="ijcp13392-app-0002" ref-type="app">B</xref>, Table <xref rid="ijcp13392-tbl-0003" ref-type="table">B2</xref>. The Nycocard&#x02122; Reader II (n&#x000a0;=&#x000a0;7) and the Alere Afininion AS100 Analyzer (n&#x000a0;=&#x000a0;6), both manufactured by Alere, had the most evaluations in the literature.</p></sec><sec id="ijcp13392-sec-0020"><label>3.4.3</label><title>D&#x02010;Dimer</title><p>D&#x02010;dimer is a protein fragment produced when a blood clot dissolves in the body. High levels of d&#x02010;dimer are therefore typically used to assess the risk of thrombotic episodes and to exclude conditions such as deep vein thrombosis and pulmonary embolism.<xref rid="ijcp13392-bib-0015" ref-type="ref">15</xref> In Appendix <xref rid="ijcp13392-app-0002" ref-type="app">B</xref>, Table <xref rid="ijcp13392-tbl-0004" ref-type="table">B3</xref>, a list of the 6 D&#x02010;Dimer POCTs that were identified during the review is provided.</p></sec><sec id="ijcp13392-sec-0021"><label>3.4.4</label><title>Influenza and respiratory syncytial virus</title><p>Respiratory syncytial virus (RSV) is a common virus that causes lower respiratory tract infections, especially in infants and toddlers. Since reinfection occurs throughout life, specifically during fall and winter, GPs and emergency departments are typically met with a surge of patient visits during these colder months.<xref rid="ijcp13392-bib-0016" ref-type="ref">16</xref> Influenza, more commonly known as the flu, is also particularly prevalent in children during winter months, causing a similar seasonal overflow of patients. Influenza is an infectious disease that causes febrile and respiratory illnesses, but typically remains undiagnosed since symptoms overlap significantly with other viral or bacterial infections.<xref rid="ijcp13392-bib-0017" ref-type="ref">17</xref> POC devices for RSV and influenza can have a major positive impact on patient care by reducing both unnecessary diagnostic testing and antibiotic prescriptions.<xref rid="ijcp13392-bib-0017" ref-type="ref">17</xref> A list of 6 POCTs for Influenza and RSV, that were identified during the review is provided in Appendix <xref rid="ijcp13392-app-0002" ref-type="app">B</xref>, Table <xref rid="ijcp13392-tbl-0005" ref-type="table">B4</xref>.</p></sec><sec id="ijcp13392-sec-0022"><label>3.4.5</label><title>Other frequently evaluated POCTs</title><p>In addition to the above&#x02010;listed POCTs, there were also tests measuring calprotectin, streptococcus pyogenes, BNP and NT&#x02010;proBNP, bladder carcinoma, uric acid, INR, IgA deficiency and chlamydia, among others. The majority of these tests had only one evaluation. A list of tests that have been evaluated more than once is provided in Appendix <xref rid="ijcp13392-app-0002" ref-type="app">B</xref>, Table <xref rid="ijcp13392-tbl-0006" ref-type="table">B5</xref>.</p></sec></sec></sec><sec sec-type="discussion" id="ijcp13392-sec-0023"><label>4</label><title>DISCUSSION</title><p>There was a clear inconsistency between what is reported on in the identified evaluations and what GPs consider important. Certain determinants of the published list used in this review are not relevant to a POCT, but rather to the disease prevalence and the GP and his practice (frequency of use, room for innovation, risks). These determinants were, as expected, underreported. None of the evaluations addressed any aspect related to room for innovation, whereas only one evaluation assessed the risk aspect of the test. Frequency of use was addressed in five of the test evaluations. Reimbursement (n&#x000a0;=&#x000a0;2) and legislations (n&#x000a0;=&#x000a0;3) were also rarely reported on in the evaluations. This could be since the impact of these determinants will vary between countries and were therefore purposefully excluded from the evaluations. The most relevant inconsistency was with clinical utility. Although GPs perceive clinical utility as the most important aspect when it comes to POCT, it was rarely explicitly included in the test evaluations found in the review. Only 8% of evaluations incorporated some aspect of clinical utility in their analysis and/or discussion. Although the definition of clinical utility used in this paper was broad to ensure that it encompasses all aspects of clinical utility, it could be that certain aspects described in the test evaluations were not accounted for. One reason for the clinical utility of a test only rarely being mentioned, could be the fact that clinical utility is often implied rather than being described. For example by pointing out that current testing and decision making is sub&#x02010;optimal without explicitly indicating how POCT would improve this. Furthermore, the turn&#x02010;around&#x02010;time of the test was reported in more than half of the evaluations (52.5%) even though it is not among the ten most important determinants according to GPs. This could possibly be because of GPs expectations that user friendliness and short turn&#x02010;around&#x02010;time are evident properties of a POCT; which is why these properties are considered a high priority in the evaluation of POCTs. Technical performance is considered the second most important determinant among GPs and it was addressed by almost half of the evaluations (48.3%).</p><p>In a study by Huddy et al,<xref rid="ijcp13392-bib-0018" ref-type="ref">18</xref> clinicians stated during interviews that POC devices with the ability to perform multiple tests (such as HbA1c combined with lipids) was seen as an additional incentive for purchasing. This could explain the high number of evaluations found in this review for the Nycocard&#x02122; Reader II (Seven evaluations for CRP, two for HbA1c and one for D&#x02010;Dimer) and the Alere Afininion AS100 Analyzer (Six evaluations for CRP and six for HbA1c). However, not all of the multiple&#x02010;test devices had a high amount of evaluations. For example the AQT90 FLEX immunoassay analyser can perform six tests (D&#x02010;dimer, Procalcitonin, CRP, NT&#x02010;proBNP, Troponin T and Troponin I), yet only one evaluation, in this case of its D&#x02010;Dimer test, was identified in the review. However, since this instrument requires a large volume of blood, and therefore a venipuncture instead of a fingerpick, it may not be considered as a POCT.<xref rid="ijcp13392-bib-0019" ref-type="ref">19</xref> Therefore, studies investigating this multiple&#x02010;test device (or similar devices) without using POCT terminology may have been missed.</p><p>Care should be taken when interpreting the absolute number of evaluations per test, as some tests may have been available on the market longer than others, and could, therefore, have been evaluated more over the years. With respect to the aforementioned tests, the earliest year that information regarding the AQT90 FLEX was found, was in 2010, with the one test evaluation in this review being from 2015. For the Nycocard&#x02122; Reader II, the earliest information about the test is from 2008, with the 11 test evaluations in this review being from 2009 (n&#x000a0;=&#x000a0;2), 2010 (n&#x000a0;=&#x000a0;2), 2011 (n&#x000a0;=&#x000a0;1), 2013 (n&#x000a0;=&#x000a0;3), 2015 (n&#x000a0;=&#x000a0;2).</p><p>There are some POCTs that did not have as many evaluations in this review, for example INR testing. Although POC INR testing is used in some outpatient labs and anticoagulation clinics, the reference standard remains clinical laboratory testing.<xref rid="ijcp13392-bib-0020" ref-type="ref">20</xref> The use of POC INR testing has become popular for at&#x02010;home testing, where patients can easily use the device to monitor their INR and report their results to a clinician (either in person or via telephone) who would then adjust their anticoagulant dose, if necessary. Another use is for patient self&#x02010;management, where patients not only tests their INR themselves but can self&#x02010;adjust their dose using a predetermined algorithm or protocol.<xref rid="ijcp13392-bib-0021" ref-type="ref">21</xref>, <xref rid="ijcp13392-bib-0022" ref-type="ref">22</xref> While some of the POCTs may also be applied by patients themselves, the focus of this review was related to the application of these tests in general practice. If an evaluation was on self&#x02010;testing, it was not included.</p><p>It is worth mentioning, that a large number (n&#x000a0;=&#x000a0;33; 39.2%) of the 84 identified tests are manufactured by only four companies, namely Alere (n&#x000a0;=&#x000a0;13), Roche (n&#x000a0;=&#x000a0;11), Quidel (n&#x000a0;=&#x000a0;5) and pts Diagnostics (n&#x000a0;=&#x000a0;4), whereas the remainder of the tests (n&#x000a0;=&#x000a0;51) are manufactured by a total of 44 different companies. The POCTs manufactured by these four companies, also have the most test evaluations. In total, almost half (n&#x000a0;=&#x000a0;71; 47.0%) of the 151 evaluations in this review were of tests manufactured by them, with 34, 19, 9 and 9 evaluations of tests manufactured by Alere, Roche, Quidel and pts Diagnostics, respectively. Although test evaluation studies are, in most cases, performed to collect (additional) evidence on test performance and added value, they may also serve the purpose to increase awareness of test availability amongst care professionals.</p><p>The biggest limitation of this review was missing studies because of not reporting the names or manufacturer of the POCT being evaluated. Furthermore, devices that have been discontinued or renamed provided further reduced the evidence base. Both of these factors could cause bias in the conclusions. Additional bias could also be caused because of the limited test selection (only applied studies in primary care). It is possible that by excluding evaluations of devices in secondary care, some tests applicable to primary as well were missed. However, if a POCT is truly relevant to primary care, it is expected that at least one study evaluating it in a primary care setting would have been found. Some of the identified tests have, presumably, been available on the market for a longer period of time that others. This makes the absolute number of evaluations per test hard to interpret. The determinants investigated in this review was identified by<xref rid="ijcp13392-bib-0012" ref-type="ref">12</xref> based on a review of existing literature. The relative importance of each determinant, however, could be specific to Dutch GPs and two specific POCTs were used as reference when assigning weights. It is therefore uncertain whether the determinants and their relative importance can be transferred to other POCTs and settings.</p><p>This review showed that, despite the growing market and rapid development of new POCTs, studies evaluating such tests fail to report on some of the key factors in the adoption of important innovative diagnostics in primary care. To ensure that an evaluation of a point&#x02010;of&#x02010;care test is useful to primary care clinicians, future evaluations should not only focus on the technical performance aspects of a test, but also report on the aspects relating to the clinical utility and risks.</p></sec><sec sec-type="COI-statement" id="ijcp13392-sec-0024"><title>DISCLOSURES</title><p>None.</p></sec><sec id="ijcp13392-sec-0025"><title>AUTHOR CONTRIBUTIONS</title><p>All authors contributed to the design of the study. DL and HK developed the search strategy. DL performed the data extraction and synthesis. All authors contributed to the selection procedure, data interpretation, data analysis, result interpretation, discussions, drafting of the manuscript and approved the final version of the manuscript for submission.</p></sec></body><back><ack id="ijcp13392-sec-0026"><title>ACKNOWLEDGEMENTS</title><p>None.</p></ack><ref-list content-type="cited-references" id="ijcp13392-bibl-0001"><title>REFERENCES</title><ref id="ijcp13392-bib-0001"><label>1</label><mixed-citation publication-type="journal" id="ijcp13392-cit-0001">
<string-name>
<surname>Howick</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Cals</surname>
<given-names>JW</given-names>
</string-name>, <string-name>
<surname>Jones</surname>
<given-names>C</given-names>
</string-name>. <article-title>Current and future use of point&#x02010;of&#x02010;care tests in primary care: an international survey in Australia, Belgium, The Netherlands, the UK and the USA</article-title>. <source xml:lang="en">BMJ Open</source>. <year>2014</year>;<volume>4</volume>:<fpage>e005611</fpage>.</mixed-citation></ref><ref id="ijcp13392-bib-0002"><label>2</label><mixed-citation publication-type="journal" id="ijcp13392-cit-0002">
<string-name>
<surname>Bossuyt</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Reitsma</surname>
<given-names>JB</given-names>
</string-name>, <string-name>
<surname>Linnet</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Moons</surname>
<given-names>K</given-names>
</string-name>. <article-title>Beyond diagnostic accuracy: the clinical utility of diagnostic tests</article-title>. <source xml:lang="en">Clin Chem</source>. <year>2012</year>;<volume>58</volume>:<fpage>1636</fpage>&#x02010;<lpage>1643</lpage>.<pub-id pub-id-type="pmid">22730450</pub-id></mixed-citation></ref><ref id="ijcp13392-bib-0003"><label>3</label><mixed-citation publication-type="journal" id="ijcp13392-cit-0003">
<string-name>
<surname>Drenck</surname>
<given-names>N&#x02010;E</given-names>
</string-name>. <article-title>Point of care testing in Critical Care Medicine: the clinician&#x02019;s view</article-title>. <source xml:lang="en">Clin Chim Acta</source>. <year>2001</year>;<volume>307</volume>:<fpage>3</fpage>&#x02010;<lpage>7</lpage>.<pub-id pub-id-type="pmid">11369329</pub-id></mixed-citation></ref><ref id="ijcp13392-bib-0004"><label>4</label><mixed-citation publication-type="journal" id="ijcp13392-cit-0004">
<string-name>
<surname>Mor</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Waisman</surname>
<given-names>Y</given-names>
</string-name>. <article-title>Point&#x02010;of&#x02010;care testing: a critical review</article-title>. <source xml:lang="en">Pediatr Emerg Care</source>. <year>2000</year>;<volume>16</volume>:<fpage>45</fpage>&#x02010;<lpage>48</lpage>.<pub-id pub-id-type="pmid">10698145</pub-id></mixed-citation></ref><ref id="ijcp13392-bib-0005"><label>5</label><mixed-citation publication-type="journal" id="ijcp13392-cit-0005">
<string-name>
<surname>Drain</surname>
<given-names>PK</given-names>
</string-name>, <string-name>
<surname>Hyle</surname>
<given-names>EP</given-names>
</string-name>, <string-name>
<surname>Noubary</surname>
<given-names>F</given-names>
</string-name>, et al. <article-title>Diagnostic point&#x02010;of&#x02010;care tests in resource&#x02010;limited settings</article-title>. <source xml:lang="en">Lancet Infect Dis</source>. <year>2014</year>;<volume>14</volume>:<fpage>239</fpage>&#x02010;<lpage>249</lpage>.<pub-id pub-id-type="pmid">24332389</pub-id></mixed-citation></ref><ref id="ijcp13392-bib-0006"><label>6</label><mixed-citation publication-type="journal" id="ijcp13392-cit-0006">
<string-name>
<surname>Hobbs</surname>
<given-names>F</given-names>
</string-name>, <string-name>
<surname>Delaney</surname>
<given-names>B</given-names>
</string-name>, <string-name>
<surname>Fitzmaurice</surname>
<given-names>DA</given-names>
</string-name>, et al. <article-title>A review of near patient testing in primary care</article-title>. <source xml:lang="en">Health Technol Assess (Rockv)</source>. <year>1997</year>;<volume>1</volume>:<fpage>i</fpage>&#x02010;<lpage>v</lpage>.</mixed-citation></ref><ref id="ijcp13392-bib-0007"><label>7</label><mixed-citation publication-type="journal" id="ijcp13392-cit-0007">
<string-name>
<surname>Luppa</surname>
<given-names>PB</given-names>
</string-name>, <string-name>
<surname>M&#x000fc;ller</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Schlichtiger</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Schlebusch</surname>
<given-names>H</given-names>
</string-name>. <article-title>Point&#x02010;of&#x02010;care testing (POCT): current techniques and future perspectives</article-title>. <source xml:lang="en">Trends Anal Chem</source>. <year>2011</year>;<volume>30</volume>:<fpage>887</fpage>&#x02010;<lpage>898</lpage>.</mixed-citation></ref><ref id="ijcp13392-bib-0008"><label>8</label><mixed-citation publication-type="book" id="ijcp13392-cit-0008">
<collab collab-type="authors">Zion Market Research</collab>
. <source xml:lang="en">Point Of Care Diagnostics Market by Products, by Prescription Mode (Prescription&#x02010;Based Testing Kits and Over&#x02010;the&#x02010;Counter Testing Kits) Market for Hospitals</source>. <publisher-loc>Clinics and Ambulatory Care Settings</publisher-loc>: <publisher-name>Global Industry Perspective, Comprehensive Analysis and Forecast</publisher-name>; <year>2017</year>:<fpage>2016</fpage>&#x02010;<lpage>2022</lpage>.</mixed-citation></ref><ref id="ijcp13392-bib-0009"><label>9</label><mixed-citation publication-type="journal" id="ijcp13392-cit-0009">
<string-name>
<surname>Jones</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Howick</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Roberts</surname>
<given-names>NW</given-names>
</string-name>, et al. <article-title>Primary care clinicians&#x02019; attitudes towards point&#x02010;of&#x02010;care blood testing: a systematic review of qualitative studies</article-title>. <source xml:lang="en">BMC Fam Pract</source>. <year>2013</year>;<volume>14</volume>:<fpage>117</fpage>.<pub-id pub-id-type="pmid">23945264</pub-id></mixed-citation></ref><ref id="ijcp13392-bib-0010"><label>10</label><mixed-citation publication-type="journal" id="ijcp13392-cit-0010">
<string-name>
<surname>Turner</surname>
<given-names>PJ</given-names>
</string-name>, <string-name>
<surname>Van den Bruel</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Jones</surname>
<given-names>C</given-names>
</string-name>, et al. <article-title>Point&#x02010;of&#x02010;care testing in UK primary care: a survey to establish clinical needs</article-title>. <source xml:lang="en">Fam Pract</source>. <year>2016</year>;<volume>33</volume>:<fpage>388</fpage>&#x02010;<lpage>394</lpage>.<pub-id pub-id-type="pmid">27048525</pub-id></mixed-citation></ref><ref id="ijcp13392-bib-0011"><label>11</label><mixed-citation publication-type="journal" id="ijcp13392-cit-0011">
<string-name>
<surname>Cals</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Schols</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>van Weert</surname>
<given-names>H</given-names>
</string-name>, et al. <article-title>Sneltesten in de huisartspraktijk: Huidig gebruik en behoefte aan testen in de toekomst</article-title>. <source xml:lang="en">Ned Tijdschr Geneeskd</source>. <year>2014</year>;<volume>158</volume>:<fpage>A8210</fpage>.<pub-id pub-id-type="pmid">25515388</pub-id></mixed-citation></ref><ref id="ijcp13392-bib-0012"><label>12</label><mixed-citation publication-type="journal" id="ijcp13392-cit-0012">
<string-name>
<surname>Kip</surname>
<given-names>MA</given-names>
</string-name>, <string-name>
<surname>Hummel</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Eppink</surname>
<given-names>E</given-names>
</string-name>, et al. <article-title>Understanding the adoption and use of point&#x02010;of&#x02010;care tests in Dutch general practices using multi&#x02010;criteria decision analysis</article-title>. <source xml:lang="en">BMC Fam Pract</source>. <year>2019</year>;<volume>20</volume>:<fpage>8</fpage>.<pub-id pub-id-type="pmid">30630430</pub-id></mixed-citation></ref><ref id="ijcp13392-bib-0013"><label>13</label><mixed-citation publication-type="journal" id="ijcp13392-cit-0013">
<string-name>
<surname>Kristensen</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Waldorff</surname>
<given-names>FB</given-names>
</string-name>, <string-name>
<surname>Nex&#x000f8;e</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Skovsgaard</surname>
<given-names>CV</given-names>
</string-name>, <string-name>
<surname>Olsen</surname>
<given-names>KR</given-names>
</string-name>. <article-title>Variation in point&#x02010;of&#x02010;care testing of HbA1c in diabetes care in general practice</article-title>. <source xml:lang="en">Int J Environ Res Public Health</source>. <year>2017</year>;<volume>14</volume>:<fpage>1363</fpage>.</mixed-citation></ref><ref id="ijcp13392-bib-0014"><label>14</label><mixed-citation publication-type="journal" id="ijcp13392-cit-0014">
<string-name>
<surname>Minnaard</surname>
<given-names>MC</given-names>
</string-name>, <string-name>
<surname>van de Pol</surname>
<given-names>AC</given-names>
</string-name>, <string-name>
<surname>Hopstaken</surname>
<given-names>RM</given-names>
</string-name>, et al. <article-title>C&#x02010;reactive protein point&#x02010;of&#x02010;care testing and associated antibiotic prescribing</article-title>. <source xml:lang="en">Fam Pract</source>. <year>2016</year>;<volume>33</volume>:<fpage>408</fpage>&#x02010;<lpage>413</lpage>.<pub-id pub-id-type="pmid">27230745</pub-id></mixed-citation></ref><ref id="ijcp13392-bib-0015"><label>15</label><mixed-citation publication-type="journal" id="ijcp13392-cit-0015">
<string-name>
<surname>Greenberg</surname>
<given-names>CS</given-names>
</string-name>. <article-title>The role of D&#x02010;dimer testing in Clinical Hematology and Oncology</article-title>. <source xml:lang="en">Clin Adv Hematol Oncol</source>. <year>2017</year>;<volume>15</volume>:<fpage>580</fpage>&#x02010;<lpage>583</lpage>.<pub-id pub-id-type="pmid">28949944</pub-id></mixed-citation></ref><ref id="ijcp13392-bib-0016"><label>16</label><mixed-citation publication-type="journal" id="ijcp13392-cit-0016">
<string-name>
<surname>Leonardi</surname>
<given-names>GP</given-names>
</string-name>, <string-name>
<surname>Wilson</surname>
<given-names>AM</given-names>
</string-name>, <string-name>
<surname>Dauz</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Zuretti</surname>
<given-names>AR</given-names>
</string-name>. <article-title>Evaluation of respiratory syncytial virus (RSV) direct antigen detection assays for use in point&#x02010;of&#x02010;care testing</article-title>. <source xml:lang="en">J Virol Methods</source>. <year>2015</year>;<volume>213</volume>:<fpage>131</fpage>&#x02010;<lpage>134</lpage>.<pub-id pub-id-type="pmid">25500182</pub-id></mixed-citation></ref><ref id="ijcp13392-bib-0017"><label>17</label><mixed-citation publication-type="journal" id="ijcp13392-cit-0017">
<string-name>
<surname>Poehling</surname>
<given-names>KA</given-names>
</string-name>, <string-name>
<surname>Zhu</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Tang</surname>
<given-names>YW</given-names>
</string-name>, <string-name>
<surname>Edwards</surname>
<given-names>K</given-names>
</string-name>. <article-title>Accuracy and impact of a point&#x02010;of&#x02010;care rapid influenza test in young children with respiratory illnesses</article-title>. <source xml:lang="en">Arch Pediatr Adolesc Med</source>. <year>2006</year>;<volume>160</volume>:<fpage>713</fpage>&#x02010;<lpage>718</lpage>.<pub-id pub-id-type="pmid">16818837</pub-id></mixed-citation></ref><ref id="ijcp13392-bib-0018"><label>18</label><mixed-citation publication-type="journal" id="ijcp13392-cit-0018">
<string-name>
<surname>Huddy</surname>
<given-names>JR</given-names>
</string-name>, <string-name>
<surname>Ni</surname>
<given-names>MZ</given-names>
</string-name>, <string-name>
<surname>Barlow</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Majeed</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Hanna</surname>
<given-names>GB</given-names>
</string-name>. <article-title>Point&#x02010;of&#x02010;care C reactive protein for the diagnosis of lower respiratory tract infection in NHS primary care: a qualitative study of barriers and facilitators to adoption</article-title>. <source xml:lang="en">BMJ Open</source>. <year>2016</year>;<volume>6</volume>:<fpage>1</fpage>&#x02010;<lpage>10</lpage>.</mixed-citation></ref><ref id="ijcp13392-bib-0019"><label>19</label><mixed-citation publication-type="journal" id="ijcp13392-cit-0019">
<string-name>
<surname>Schols</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Dinant</surname>
<given-names>GJ</given-names>
</string-name>, <string-name>
<surname>Hopstaken</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Price</surname>
<given-names>CP</given-names>
</string-name>, <string-name>
<surname>Kusters</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Cals</surname>
<given-names>J</given-names>
</string-name>. <article-title>International definition of a point&#x02010;of&#x02010;care test in family practice: a modified e&#x02010;Delphi procedure</article-title>. <source xml:lang="en">Fam Pract</source>. <year>2018</year>;<volume>35</volume>:<fpage>475</fpage>&#x02010;<lpage>480</lpage>.<pub-id pub-id-type="pmid">29385437</pub-id></mixed-citation></ref><ref id="ijcp13392-bib-0020"><label>20</label><mixed-citation publication-type="journal" id="ijcp13392-cit-0020">
<string-name>
<surname>Johnson</surname>
<given-names>SA</given-names>
</string-name>. <article-title>Point&#x02010;of&#x02010;care or clinical lab INR for anticoagulation monitoring: which to believe?</article-title>
<source xml:lang="en">Clin Lab New</source>. <year>2019</year>.</mixed-citation></ref><ref id="ijcp13392-bib-0021"><label>21</label><mixed-citation publication-type="journal" id="ijcp13392-cit-0021">
<string-name>
<surname>Barcellona</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Fenu</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Marongiu</surname>
<given-names>F</given-names>
</string-name>. <article-title>Point&#x02010;of&#x02010;care testing INR: an overview</article-title>. <source xml:lang="en">Clin Chem Lab Med</source>. <year>2017</year>;<volume>55</volume>:<fpage>800</fpage>&#x02010;<lpage>805</lpage>.<pub-id pub-id-type="pmid">27754958</pub-id></mixed-citation></ref><ref id="ijcp13392-bib-0022"><label>22</label><mixed-citation publication-type="miscellaneous" id="ijcp13392-cit-0022">
<collab collab-type="authors">Canadian Agency for Drugs and Technologies in Health</collab>
. <article-title>Point-of-care INR testing compared with lab INR testing: what does the evidence say?</article-title>
<year>2015</year>.</mixed-citation></ref></ref-list><app-group><app id="ijcp13392-app-0001" content-type="APPENDIX"><label>APPENDIX A</label><sec id="ijcp13392-sec-0027"><title>REVIEW PROTOCOL AND PRISMA FLOW DIAGRAM</title><fig fig-type="Figure" xml:lang="en" id="ijcp13392-fig-0002" orientation="portrait" position="anchor"><label>Figure A1</label><caption><p>Review protocol</p></caption><graphic id="nlm-graphic-3" xlink:href="IJCP-73-e13392-g002"/></fig><fig fig-type="Figure" xml:lang="en" id="ijcp13392-fig-0003" orientation="portrait" position="anchor"><label>Figure A2</label><caption><p>PRISMA flow diagram</p></caption><graphic id="nlm-graphic-5" xlink:href="IJCP-73-e13392-g003"/></fig></sec></app><app id="ijcp13392-app-0002" content-type="APPENDIX"><label>APPENDIX B</label><sec id="ijcp13392-sec-0028"><table-wrap id="ijcp13392-tbl-0002" xml:lang="en" orientation="portrait" position="anchor"><label>Table B1</label><caption><p>List of HbA1c POCTs identified from the review</p></caption><table frame="hsides" rules="groups"><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><thead valign="top"><tr style="border-bottom:solid 1px #000000"><th align="left" valign="top" rowspan="1" colspan="1">Name of Device/Analyzer/Test</th><th align="left" valign="top" rowspan="1" colspan="1">Number of studies</th><th align="left" valign="top" rowspan="1" colspan="1">Manufacturer</th><th align="left" valign="top" rowspan="1" colspan="1">Link to official site</th><th align="left" valign="top" rowspan="1" colspan="1">Measure&#x02010;ment used in study</th><th align="left" valign="top" rowspan="1" colspan="1">Other available measurements</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">A1CNow System</td><td align="left" rowspan="1" colspan="1">5</td><td align="left" rowspan="1" colspan="1">pts Diagnostics</td><td align="left" rowspan="1" colspan="1">
<ext-link ext-link-type="uri" xlink:href="http://www.ptsdiagnostics.com/a1cnow-systems-overview.html">http://www.ptsdiagnostics.com/a1cnow-systems-overview.html</ext-link>
</td><td align="left" rowspan="1" colspan="1">HbA1c</td><td align="left" rowspan="1" colspan="1">N/A</td></tr><tr><td align="left" rowspan="1" colspan="1">Cobas b 101 POC system</td><td align="left" rowspan="1" colspan="1">1</td><td align="left" rowspan="1" colspan="1">Roche</td><td align="left" rowspan="1" colspan="1">
<ext-link ext-link-type="uri" xlink:href="http://www.cobas.com/home/product/point-of-care-testing/cobas-b-101-poc-system.html">http://www.cobas.com/home/product/point-of-care-testing/cobas-b-101-poc-system.html</ext-link>
</td><td align="left" rowspan="1" colspan="1">HbA1c</td><td align="left" rowspan="1" colspan="1">HbA1c and Lipid Panel</td></tr><tr><td align="left" rowspan="1" colspan="1">Cobas b 101 POC system</td><td align="left" rowspan="1" colspan="1">1</td><td align="left" rowspan="1" colspan="1">Roche</td><td align="left" rowspan="1" colspan="1">
<ext-link ext-link-type="uri" xlink:href="http://www.cobas.com/home/product/point-of-care-testing/cobas-b-101-poc-system.html">http://www.cobas.com/home/product/point-of-care-testing/cobas-b-101-poc-system.html</ext-link>
</td><td align="left" rowspan="1" colspan="1">HbA1c and Lipid Panel</td><td align="left" rowspan="1" colspan="1">HbA1c</td></tr><tr><td align="left" rowspan="1" colspan="1">Nycocard&#x02122; Reader II</td><td align="left" rowspan="1" colspan="1">2</td><td align="left" rowspan="1" colspan="1">Abbott/Alere</td><td align="left" rowspan="1" colspan="1">
<ext-link ext-link-type="uri" xlink:href="https://www.alere.com/en/home/product-details/nycocard-reader.html">https://www.alere.com/en/home/product-details/nycocard-reader.html</ext-link>
</td><td align="left" rowspan="1" colspan="1">HbA1c</td><td align="left" rowspan="1" colspan="1">D&#x02010;Dimer, U&#x02010;Albumin, CRP</td></tr><tr><td align="left" rowspan="1" colspan="1">B&#x02010;analyst</td><td align="left" rowspan="1" colspan="1">1</td><td align="left" rowspan="1" colspan="1">Menarini diagnostics</td><td align="left" rowspan="1" colspan="1">
<ext-link ext-link-type="uri" xlink:href="http://www.menarinidiag.co.uk/Products/Haemoglobin-Analyser/B-analyst">http://www.menarinidiag.co.uk/Products/Haemoglobin-Analyser/B-analyst</ext-link>
</td><td align="left" rowspan="1" colspan="1">HbA1c</td><td align="left" rowspan="1" colspan="1">hsCRP, CRP</td></tr><tr><td align="left" rowspan="1" colspan="1">A1c EZ 2.0</td><td align="left" rowspan="1" colspan="1">1</td><td align="left" rowspan="1" colspan="1">BioHermes</td><td align="left" rowspan="1" colspan="1">
<ext-link ext-link-type="uri" xlink:href="http://en.biohermes.com/article.php?xml:id=17">http://en.biohermes.com/article.php?xml:id=17</ext-link>
</td><td align="left" rowspan="1" colspan="1">HbA1c</td><td align="left" rowspan="1" colspan="1">N/A</td></tr><tr><td align="left" rowspan="1" colspan="1">SAKAE's A1c Gear</td><td align="left" rowspan="1" colspan="1">1</td><td align="left" rowspan="1" colspan="1">SAKAE Corporation</td><td align="left" rowspan="1" colspan="1">
<ext-link ext-link-type="uri" xlink:href="http://www.sakaecorp.com/english/a1c.html">http://www.sakaecorp.com/english/a1c.html</ext-link>
</td><td align="left" rowspan="1" colspan="1">HbA1c</td><td align="left" rowspan="1" colspan="1">N/A</td></tr><tr><td align="left" rowspan="1" colspan="1">Alere Afininion AS100 Analyzer</td><td align="left" rowspan="1" colspan="1">6</td><td align="left" rowspan="1" colspan="1">Abbott/Alere</td><td align="left" rowspan="1" colspan="1">
<ext-link ext-link-type="uri" xlink:href="https://www.alere.com/en/home/product-details/afinion-as100-analyzer.html">https://www.alere.com/en/home/product-details/afinion-as100-analyzer.html</ext-link>
</td><td align="left" rowspan="1" colspan="1">HbA1c</td><td align="left" rowspan="1" colspan="1">Albumin/Creatinine Ratio, CRP, Lipid Panel</td></tr><tr><td align="left" rowspan="1" colspan="1">DCA Vantage Analyzer</td><td align="left" rowspan="1" colspan="1">8<xref ref-type="fn" rid="ijcp13392-note-0001">a</xref>
</td><td align="left" rowspan="1" colspan="1">Siemens</td><td align="left" rowspan="1" colspan="1">
<ext-link ext-link-type="uri" xlink:href="https://usa.healthcare.siemens.com/point-of-care/diabetes/dca-vantage-analyzer">https://usa.healthcare.siemens.com/point-of-care/diabetes/dca-vantage-analyzer</ext-link>
</td><td align="left" rowspan="1" colspan="1">HbA1c</td><td align="left" rowspan="1" colspan="1">Albumin/Creatinine Ratio</td></tr><tr><td align="left" rowspan="1" colspan="1">Quo&#x02010;Test&#x000ae; HbA1c Analyzer</td><td align="left" rowspan="1" colspan="1">1</td><td align="left" rowspan="1" colspan="1">EKF Diagnostics Holdings</td><td align="left" rowspan="1" colspan="1">
<ext-link ext-link-type="uri" xlink:href="https://www.ekfdiagnostics.com/quo-test.html">https://www.ekfdiagnostics.com/quo-test.html</ext-link>
</td><td align="left" rowspan="1" colspan="1">HbA1c</td><td align="left" rowspan="1" colspan="1">N/A</td></tr><tr><td align="left" rowspan="1" colspan="1">Clover A1c Analyser</td><td align="left" rowspan="1" colspan="1">1</td><td align="left" rowspan="1" colspan="1">EuroMedix</td><td align="left" rowspan="1" colspan="1">
<ext-link ext-link-type="uri" xlink:href="https://www.euromedix.com/en/product?item=22">https://www.euromedix.com/en/product?item=22</ext-link>
</td><td align="left" rowspan="1" colspan="1">HbA1c</td><td align="left" rowspan="1" colspan="1">N/A</td></tr><tr><td align="left" rowspan="1" colspan="1">in2it&#x02122; A1C</td><td align="left" rowspan="1" colspan="1">2</td><td align="left" rowspan="1" colspan="1">Bio Rad</td><td align="left" rowspan="1" colspan="1">
<ext-link ext-link-type="uri" xlink:href="http://www.bio-rad.com/webroot/web/pdf/cdg/literature/A-243_in2it_%2520A1C_brochure_DG09-0324.pdf">http://www.bio-rad.com/webroot/web/pdf/cdg/literature/A-243_in2it_%2520A1C_brochure_DG09-0324.pdf</ext-link>
</td><td align="left" rowspan="1" colspan="1">HbA1c</td><td align="left" rowspan="1" colspan="1">N/A</td></tr><tr><td align="left" rowspan="1" colspan="1">InnovaStar&#x000ae;</td><td align="left" rowspan="1" colspan="1">1</td><td align="left" rowspan="1" colspan="1">DiaSys Diagnostic Systems</td><td align="left" rowspan="1" colspan="1">
<ext-link ext-link-type="uri" xlink:href="https://www.diasys-diagnostics.com/products/poct-systems/innovastar/#tab-state-3284-3287">https://www.diasys-diagnostics.com/products/poct-systems/innovastar/#tab-state-3284-3287</ext-link>
</td><td align="left" rowspan="1" colspan="1">HbA1c</td><td align="left" rowspan="1" colspan="1">CRP, Glucose</td></tr><tr><td align="left" rowspan="1" colspan="1">LABGEO PT10</td><td align="left" rowspan="1" colspan="1">2</td><td align="left" rowspan="1" colspan="1">Samsung</td><td align="left" rowspan="1" colspan="1">
<ext-link ext-link-type="uri" xlink:href="https://www.avant-medical.com/portfolio-item/samsung-labgeo-pt-10-analyzer/">https://www.avant-medical.com/portfolio-item/samsung-labgeo-pt-10-analyzer/</ext-link>
</td><td align="left" rowspan="1" colspan="1">HbA1c</td><td align="left" rowspan="1" colspan="1">Several</td></tr></tbody></table><table-wrap-foot id="ijcp13392-ntgp-0001"><fn id="ijcp13392-note-0001"><label>a</label><p>Three of the eight studies used the DCA 2000&#x000a0;+&#x000a0;device, the predecessor of DCA Vantage.</p></fn></table-wrap-foot><permissions><copyright-holder>John Wiley &#x00026; Sons, Ltd</copyright-holder><license><license-p>This article is being made freely available through PubMed Central as part of the COVID-19 public health emergency response. It can be used for unrestricted research re-use and analysis in any form or by any means with acknowledgement of the original source, for the duration of the public health emergency.</license-p></license></permissions></table-wrap><table-wrap id="ijcp13392-tbl-0003" xml:lang="en" orientation="portrait" position="anchor"><label>Table B2</label><caption><p>List of CRP POCTs identified from the review</p></caption><table frame="hsides" rules="groups"><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><thead valign="top"><tr style="border-bottom:solid 1px #000000"><th align="left" valign="top" rowspan="1" colspan="1">Name of Device/Analyzer/Test</th><th align="left" valign="top" rowspan="1" colspan="1">Number of studies</th><th align="left" valign="top" rowspan="1" colspan="1">Manufacturer</th><th align="left" valign="top" rowspan="1" colspan="1">Link to official site</th><th align="left" valign="top" rowspan="1" colspan="1">Measure&#x02010;ment used in study</th><th align="left" valign="top" rowspan="1" colspan="1">Other available measurements</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">ABX Micros CRP 200</td><td align="left" rowspan="1" colspan="1">1</td><td align="left" rowspan="1" colspan="1">ABX Diagnostics (Horiba Medical)</td><td align="left" rowspan="1" colspan="1">
<ext-link ext-link-type="uri" xlink:href="http://www.horiba.com/us/en/medical/products/hematology/abx-micros/abx-micros-crp-200-details/abx-micros-crp-200-907/">http://www.horiba.com/us/en/medical/products/hematology/abx-micros/abx-micros-crp-200-details/abx-micros-crp-200-907/</ext-link>
</td><td align="left" rowspan="1" colspan="1">CRP</td><td align="left" rowspan="1" colspan="1">N/A</td></tr><tr><td align="left" rowspan="1" colspan="1">Alere Afininion AS100 Analyzer</td><td align="left" rowspan="1" colspan="1">6</td><td align="left" rowspan="1" colspan="1">Abbott/Alere</td><td align="left" rowspan="1" colspan="1">
<ext-link ext-link-type="uri" xlink:href="https://www.alere.com/en/home/product-details/afinion-as100-analyzer.html">https://www.alere.com/en/home/product-details/afinion-as100-analyzer.html</ext-link>
</td><td align="left" rowspan="1" colspan="1">CRP</td><td align="left" rowspan="1" colspan="1">Albumin/Creatinine Ratio, HbA1c, Lipid Panel</td></tr><tr><td align="left" rowspan="1" colspan="1">Nycocard&#x02122; Reader II</td><td align="left" rowspan="1" colspan="1">7</td><td align="left" rowspan="1" colspan="1">Abbott/Alere</td><td align="left" rowspan="1" colspan="1">
<ext-link ext-link-type="uri" xlink:href="https://www.alere.com/en/home/product-details/nycocard-reader.html">https://www.alere.com/en/home/product-details/nycocard-reader.html</ext-link>
</td><td align="left" rowspan="1" colspan="1">CRP</td><td align="left" rowspan="1" colspan="1">D&#x02010;Dimer, U&#x02010;Albumin, HbA1c</td></tr><tr><td align="left" rowspan="1" colspan="1">QuikRead 101</td><td align="left" rowspan="1" colspan="1">4</td><td align="left" rowspan="1" colspan="1">Orion Diagnostica</td><td align="left" rowspan="1" colspan="1">
<ext-link ext-link-type="uri" xlink:href="http://www.oriondiagnostica.com/Products/QuikRead/">http://www.oriondiagnostica.com/Products/QuikRead/</ext-link>
</td><td align="left" rowspan="1" colspan="1">CRP</td><td align="left" rowspan="1" colspan="1">Faecal Occult Blood, U&#x02010;Albumin</td></tr><tr><td align="left" rowspan="1" colspan="1">QuikRead Go</td><td align="left" rowspan="1" colspan="1">3</td><td align="left" rowspan="1" colspan="1">Orion Diagnostica</td><td align="left" rowspan="1" colspan="1">
<ext-link ext-link-type="uri" xlink:href="http://www.oriondiagnostica.com/Products/QuikRead-go/">http://www.oriondiagnostica.com/Products/QuikRead-go/</ext-link>
</td><td align="left" rowspan="1" colspan="1">CRP</td><td align="left" rowspan="1" colspan="1">CRP and HbA1c, Streptococcus pyogenes</td></tr><tr><td align="left" rowspan="1" colspan="1">Eurolyser Smart 700|340</td><td align="left" rowspan="1" colspan="1">2</td><td align="left" rowspan="1" colspan="1">EuroLyser Diagnostika</td><td align="left" rowspan="1" colspan="1">
<ext-link ext-link-type="uri" xlink:href="https://www.eurolyser.com/medical-diagnostics/point-of-care/smart/smart-700-340/">https://www.eurolyser.com/medical-diagnostics/point-of-care/smart/smart-700-340/</ext-link>
</td><td align="left" rowspan="1" colspan="1">CRP</td><td align="left" rowspan="1" colspan="1">15 of them</td></tr></tbody></table><permissions><copyright-holder>John Wiley &#x00026; Sons, Ltd</copyright-holder><license><license-p>This article is being made freely available through PubMed Central as part of the COVID-19 public health emergency response. It can be used for unrestricted research re-use and analysis in any form or by any means with acknowledgement of the original source, for the duration of the public health emergency.</license-p></license></permissions></table-wrap><table-wrap id="ijcp13392-tbl-0004" xml:lang="en" orientation="portrait" position="anchor"><label>Table B3</label><caption><p>List of D&#x02010;Dimer POCTs identified from the review</p></caption><table frame="hsides" rules="groups"><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><thead valign="top"><tr style="border-bottom:solid 1px #000000"><th align="left" valign="top" rowspan="1" colspan="1">Name of Device/Analyzer/Test</th><th align="left" valign="top" rowspan="1" colspan="1">Number of studies</th><th align="left" valign="top" rowspan="1" colspan="1">Manufacturer</th><th align="left" valign="top" rowspan="1" colspan="1">Link to official site</th><th align="left" valign="top" rowspan="1" colspan="1">Measure&#x02010;ment used in study</th><th align="left" valign="top" rowspan="1" colspan="1">Other available measurements</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Roche CARDIAC&#x000ae; D&#x02010;Dimer (D&#x02010;Dimer assay) on the cobas h 232 POC system</td><td align="left" rowspan="1" colspan="1">2</td><td align="left" rowspan="1" colspan="1">Roche</td><td align="left" rowspan="1" colspan="1">
<ext-link ext-link-type="uri" xlink:href="http://www.cobas.com/home/product/point-of-care-testing/cobas-h-232.html">http://www.cobas.com/home/product/point-of-care-testing/cobas-h-232.html</ext-link>
</td><td align="left" rowspan="1" colspan="1">D&#x02010;Dimer</td><td align="left" rowspan="1" colspan="1">CK&#x02010;MB, Troponin T, Myoglobin, NT&#x02010;proBNP</td></tr><tr><td align="left" rowspan="1" colspan="1">Nycocard&#x02122; Reader II</td><td align="left" rowspan="1" colspan="1">1</td><td align="left" rowspan="1" colspan="1">Abbott/Alere</td><td align="left" rowspan="1" colspan="1">
<ext-link ext-link-type="uri" xlink:href="https://www.alere.com/en/home/product-details/nycocard-reader.html">https://www.alere.com/en/home/product-details/nycocard-reader.html</ext-link>
</td><td align="left" rowspan="1" colspan="1">D&#x02010;Dimer</td><td align="left" rowspan="1" colspan="1">D&#x02010;Dimer, U&#x02010;Albumin, CRP</td></tr><tr><td align="left" rowspan="1" colspan="1">AQT90 FLEX immunoassay analyzer</td><td align="left" rowspan="1" colspan="1">1</td><td align="left" rowspan="1" colspan="1">Radiometer</td><td align="left" rowspan="1" colspan="1">
<ext-link ext-link-type="uri" xlink:href="https://www.radiometer.com/en/products/immunoassay-testing/aqt90-flex-immunoassay-analyzer/d-dimer-test-on-the-aqt90-flex-immunoassay-analyzer">https://www.radiometer.com/en/products/immunoassay-testing/aqt90-flex-immunoassay-analyzer/d-dimer-test-on-the-aqt90-flex-immunoassay-analyzer</ext-link>
</td><td align="left" rowspan="1" colspan="1">D&#x02010;dimer</td><td align="left" rowspan="1" colspan="1">Procalcitonin (PCT), CRP, NT&#x02010;proBNP, Troponin T, Troponin I</td></tr><tr><td align="left" rowspan="1" colspan="1">Triage D&#x02010;Dimer Test</td><td align="left" rowspan="1" colspan="1">2</td><td align="left" rowspan="1" colspan="1">Quidel</td><td align="left" rowspan="1" colspan="1">
<ext-link ext-link-type="uri" xlink:href="https://www.quidel.com/immunoassays/triage-test-kits/triage-d-dimer-test">https://www.quidel.com/immunoassays/triage-test-kits/triage-d-dimer-test</ext-link>
</td><td align="left" rowspan="1" colspan="1">D&#x02010;Dimer</td><td align="left" rowspan="1" colspan="1">N/A</td></tr><tr><td align="left" rowspan="1" colspan="1">PATHFAST</td><td align="left" rowspan="1" colspan="1">2</td><td align="left" rowspan="1" colspan="1">Mitsubishi Chemical Europe GmbH</td><td align="left" rowspan="1" colspan="1">
<ext-link ext-link-type="uri" xlink:href="http://www.pathfast.eu/emergency-marker">http://www.pathfast.eu/emergency-marker</ext-link>
</td><td align="left" rowspan="1" colspan="1">D&#x02010;Dimer</td><td align="left" rowspan="1" colspan="1">Troponin I, NT&#x02010;proBNP, hsCRP, Myoglobin, HCG and CK&#x02010;MB mass</td></tr><tr><td align="left" rowspan="1" colspan="1">LABGEO IB10</td><td align="left" rowspan="1" colspan="1">1</td><td align="left" rowspan="1" colspan="1">Samsung</td><td align="left" rowspan="1" colspan="1">
<ext-link ext-link-type="uri" xlink:href="https://www.tecom-as.com/en/samsung-labgeo/ib10/">https://www.tecom-as.com/en/samsung-labgeo/ib10/</ext-link>
</td><td align="left" rowspan="1" colspan="1">D&#x02010;Dimer</td><td align="left" rowspan="1" colspan="1">Troponin I, NT&#x02010;ProBNP, Troponin I and NT&#x02010;ProBNP, Troponin I and CK&#x02010;MB and myoglobin, Troponin I and NT&#x02010;ProBNP and D&#x02010;Dimer, beta&#x02010;hCG, Thyroid&#x02010;stimulating hormone, Procalcitonin (PCT)</td></tr></tbody></table><permissions><copyright-holder>John Wiley &#x00026; Sons, Ltd</copyright-holder><license><license-p>This article is being made freely available through PubMed Central as part of the COVID-19 public health emergency response. It can be used for unrestricted research re-use and analysis in any form or by any means with acknowledgement of the original source, for the duration of the public health emergency.</license-p></license></permissions></table-wrap><table-wrap id="ijcp13392-tbl-0005" xml:lang="en" orientation="portrait" position="anchor"><label>Table B4</label><caption><p>List of Influenza and RSV POCTs identified from the review</p></caption><table frame="hsides" rules="groups"><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><thead valign="top"><tr style="border-bottom:solid 1px #000000"><th align="left" valign="top" rowspan="1" colspan="1">Name of Device/Analyzer/Test</th><th align="left" valign="top" rowspan="1" colspan="1">Number of Studies</th><th align="left" valign="top" rowspan="1" colspan="1">Manufacturer</th><th align="left" valign="top" rowspan="1" colspan="1">Link to official site</th><th align="left" valign="top" rowspan="1" colspan="1">Measure&#x02010;ment used in study</th><th align="left" valign="top" rowspan="1" colspan="1">Other available measurements</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">cobas&#x000ae; Liat&#x000ae; PCR System</td><td align="left" rowspan="1" colspan="1">1</td><td align="left" rowspan="1" colspan="1">Roche</td><td align="left" rowspan="1" colspan="1">
<ext-link ext-link-type="uri" xlink:href="https://www.cobasliat.com/">https://www.cobasliat.com/</ext-link>
</td><td align="left" rowspan="1" colspan="1">Influenza A and Influenza B</td><td align="left" rowspan="1" colspan="1">Streptococcus pyogenes group A, Influenza A and Influenza B and RSV, Cdiff, MRSA/SA</td></tr><tr><td align="left" rowspan="1" colspan="1">cobas&#x000ae; Liat&#x000ae; PCR System</td><td align="left" rowspan="1" colspan="1">1</td><td align="left" rowspan="1" colspan="1">Roche</td><td align="left" rowspan="1" colspan="1">
<ext-link ext-link-type="uri" xlink:href="https://www.cobasliat.com/">https://www.cobasliat.com/</ext-link>
</td><td align="left" rowspan="1" colspan="1">Influenza A and Influenza B and RSV</td><td align="left" rowspan="1" colspan="1">Streptococcus pyogenes group A, Influenza A and Influenza B, Cdiff, MRSA/SA</td></tr><tr><td align="left" rowspan="1" colspan="1">mariPOC&#x000ae; (Respi test)</td><td align="left" rowspan="1" colspan="1">4</td><td align="left" rowspan="1" colspan="1">ArcDia</td><td align="left" rowspan="1" colspan="1">
<ext-link ext-link-type="uri" xlink:href="http://www.arcdia.com/eng/maripoc/introduction/">http://www.arcdia.com/eng/maripoc/introduction/</ext-link>
</td><td align="left" rowspan="1" colspan="1">Influenza A and Influenza B</td><td align="left" rowspan="1" colspan="1">Influenza A virus and Influenza B virus and Respiratory syncytial virus and Human Coronavirus OC43 and Human metapneumovirus and Human bocavirus and Parainfluenza virus type 1 and Parainfluenza virus type 2 and Parainfluenza virus type 3 and Adenovirus and Streptococcus pneumoniae</td></tr><tr><td align="left" rowspan="1" colspan="1">Alere&#x02122; i</td><td align="left" rowspan="1" colspan="1">1</td><td align="left" rowspan="1" colspan="1">Abbott/Alere</td><td align="left" rowspan="1" colspan="1">
<ext-link ext-link-type="uri" xlink:href="https://www.alere.com/en/home/product-details/alere-i.html">https://www.alere.com/en/home/product-details/alere-i.html</ext-link>
</td><td align="left" rowspan="1" colspan="1">Influenza A and Influenza B</td><td align="left" rowspan="1" colspan="1">RSV, Streptococcus pyogenes group A</td></tr><tr><td align="left" rowspan="1" colspan="1">BD Veritor&#x02122; Plus system</td><td align="left" rowspan="1" colspan="1">1</td><td align="left" rowspan="1" colspan="1">Becton, Dickinson and Company (BD)</td><td align="left" rowspan="1" colspan="1">
<ext-link ext-link-type="uri" xlink:href="https://www.bd.com/en-us/offerings/capabilities/microbiology-solutions/point-of-care-testing/veritor-plus-system">https://www.bd.com/en-us/offerings/capabilities/microbiology-solutions/point-of-care-testing/veritor-plus-system</ext-link>
</td><td align="left" rowspan="1" colspan="1">RSV</td><td align="left" rowspan="1" colspan="1">Influenza A and Influenza B</td></tr><tr><td align="left" rowspan="1" colspan="1">QuickVue Influenza A&#x000a0;+&#x000a0;B Test</td><td align="left" rowspan="1" colspan="1">2</td><td align="left" rowspan="1" colspan="1">Quidel</td><td align="left" rowspan="1" colspan="1">
<ext-link ext-link-type="uri" xlink:href="https://www.quidel.com/immunoassays/rapid-influenza-tests/quickvue-influenza-test">https://www.quidel.com/immunoassays/rapid-influenza-tests/quickvue-influenza-test</ext-link>
</td><td align="left" rowspan="1" colspan="1">Influenza A&#x000a0;+&#x000a0;B</td><td align="left" rowspan="1" colspan="1">N/A</td></tr></tbody></table><permissions><copyright-holder>John Wiley &#x00026; Sons, Ltd</copyright-holder><license><license-p>This article is being made freely available through PubMed Central as part of the COVID-19 public health emergency response. It can be used for unrestricted research re-use and analysis in any form or by any means with acknowledgement of the original source, for the duration of the public health emergency.</license-p></license></permissions></table-wrap><table-wrap id="ijcp13392-tbl-0006" xml:lang="en" orientation="portrait" position="anchor"><label>Table B5</label><caption><p>List of other frequently evaluated POCTs identified from the review</p></caption><table frame="hsides" rules="groups"><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><thead valign="top"><tr style="border-bottom:solid 1px #000000"><th align="left" valign="top" rowspan="1" colspan="1">Name of Device/Analyzer/Test</th><th align="left" valign="top" rowspan="1" colspan="1">Number of studies</th><th align="left" valign="top" rowspan="1" colspan="1">Manufacturer</th><th align="left" valign="top" rowspan="1" colspan="1">Link to official site</th><th align="left" valign="top" rowspan="1" colspan="1">Measure&#x02010;ment used in study</th><th align="left" valign="top" rowspan="1" colspan="1">Other available measurements</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">AUTION ELEVEN AE&#x02010;4020</td><td align="left" rowspan="1" colspan="1">3</td><td align="left" rowspan="1" colspan="1">Arkray/A.Menarini Diagnostics</td><td align="left" rowspan="1" colspan="1">
<ext-link ext-link-type="uri" xlink:href="http://www.arkray.eu/english/products/laboratory/analyzers/ae-4020.html">http://www.arkray.eu/english/products/laboratory/analyzers/ae-4020.html</ext-link>
</td><td align="left" rowspan="1" colspan="1">Urine analysis</td><td align="left" rowspan="1" colspan="1">N/A</td></tr><tr><td align="left" rowspan="1" colspan="1">Urisys 1100&#x000ae;</td><td align="left" rowspan="1" colspan="1">2</td><td align="left" rowspan="1" colspan="1">Roche</td><td align="left" rowspan="1" colspan="1">
<ext-link ext-link-type="uri" xlink:href="http://www.cobas.com/home/product/urinalysis-testing/urisys-1100-urine-analyzer.html">http://www.cobas.com/home/product/urinalysis-testing/urisys-1100-urine-analyzer.html</ext-link>
</td><td align="left" rowspan="1" colspan="1">Urine analysis</td><td align="left" rowspan="1" colspan="1">N/A</td></tr><tr><td align="left" rowspan="1" colspan="1">Quantum Blue&#x000ae; fCAL</td><td align="left" rowspan="1" colspan="1">3</td><td align="left" rowspan="1" colspan="1">Buhlmann Labs</td><td align="left" rowspan="1" colspan="1">
<ext-link ext-link-type="uri" xlink:href="https://www.buhlmannlabs.ch/products-solutions/quantum-blue/calprotectin/">https://www.buhlmannlabs.ch/products-solutions/quantum-blue/calprotectin/</ext-link>
</td><td align="left" rowspan="1" colspan="1">fCAL</td><td align="left" rowspan="1" colspan="1">Adalimumab, CRP, Infliximab</td></tr><tr><td align="left" rowspan="1" colspan="1">Triage BNP Test used with the Quidel Triage MeterPro</td><td align="left" rowspan="1" colspan="1">3</td><td align="left" rowspan="1" colspan="1">Quidel</td><td align="left" rowspan="1" colspan="1">
<ext-link ext-link-type="uri" xlink:href="https://www.quidel.com/immunoassays/triage-test-kits/triage-bnp-test">https://www.quidel.com/immunoassays/triage-test-kits/triage-bnp-test</ext-link>
</td><td align="left" rowspan="1" colspan="1">BNP</td><td align="left" rowspan="1" colspan="1">CK&#x02010;MB and Myoglobin and Troponin I, Troponin I and BNP, CK&#x02010;MB and Troponin I and BNP, Troponin I and CK&#x02010;MB and myoglobin and BNP and D&#x02010;dimer, Troponin I</td></tr><tr><td align="left" rowspan="1" colspan="1">CoaguChek&#x000ae; XS system</td><td align="left" rowspan="1" colspan="1">5</td><td align="left" rowspan="1" colspan="1">Roche</td><td align="left" rowspan="1" colspan="1">
<ext-link ext-link-type="uri" xlink:href="http://www.coaguchek.com/coaguchek_patient/en/home/products/xs-system.html">http://www.coaguchek.com/coaguchek_patient/en/home/products/xs-system.html</ext-link>
</td><td align="left" rowspan="1" colspan="1">INR</td><td align="left" rowspan="1" colspan="1">N/A</td></tr><tr><td align="left" rowspan="1" colspan="1">Alere Cholestech LDX&#x000ae; Analyzer</td><td align="left" rowspan="1" colspan="1">5</td><td align="left" rowspan="1" colspan="1">Abbott/Alere</td><td align="left" rowspan="1" colspan="1">
<ext-link ext-link-type="uri" xlink:href="https://www.alere.com/en/home/product-details/cholestech-ldx-system.html">https://www.alere.com/en/home/product-details/cholestech-ldx-system.html</ext-link>
</td><td align="left" rowspan="1" colspan="1">Lipid Panel</td><td align="left" rowspan="1" colspan="1">N/A</td></tr><tr><td align="left" rowspan="1" colspan="1">CardioChek&#x000ae; PA Analyzer</td><td align="left" rowspan="1" colspan="1">2</td><td align="left" rowspan="1" colspan="1">pts Diagnostics</td><td align="left" rowspan="1" colspan="1">
<ext-link ext-link-type="uri" xlink:href="http://www.ptsdiagnostics.com/cardiochek-pa.html">http://www.ptsdiagnostics.com/cardiochek-pa.html</ext-link>
</td><td align="left" rowspan="1" colspan="1">High density lipoprotein (HDL)</td><td align="left" rowspan="1" colspan="1">Glucose, Total Cholesterol, Triglycerides</td></tr><tr><td align="left" rowspan="1" colspan="1">Biocard&#x02122; Celiac Test</td><td align="left" rowspan="1" colspan="1">3</td><td align="left" rowspan="1" colspan="1">Labsystems Diagnostics</td><td align="left" rowspan="1" colspan="1">
<ext-link ext-link-type="uri" xlink:href="https://www.labsystemsdx.com/products/gastroenterology/biocard-celiac-test">https://www.labsystemsdx.com/products/gastroenterology/biocard-celiac-test</ext-link>
</td><td align="left" rowspan="1" colspan="1">IgA deficiency</td><td align="left" rowspan="1" colspan="1">N/A</td></tr><tr><td align="left" rowspan="1" colspan="1">Xpert&#x000ae; MTB/RIF</td><td align="left" rowspan="1" colspan="1">2</td><td align="left" rowspan="1" colspan="1">Cepheid</td><td align="left" rowspan="1" colspan="1">
<ext-link ext-link-type="uri" xlink:href="http://www.cepheid.com/en/cepheid-solutions/clinical-ivd-tests/critical-infectious-diseases/xpert-mtb-rif">http://www.cepheid.com/en/cepheid-solutions/clinical-ivd-tests/critical-infectious-diseases/xpert-mtb-rif</ext-link>
</td><td align="left" rowspan="1" colspan="1">MTB and Rifampin&#x02010;Resistance Mutations</td><td align="left" rowspan="1" colspan="1">N/A</td></tr><tr><td align="left" rowspan="1" colspan="1">CardioDetect med</td><td align="left" rowspan="1" colspan="1">2</td><td align="left" rowspan="1" colspan="1">rennesens GmbH</td><td align="left" rowspan="1" colspan="1">
<ext-link ext-link-type="uri" xlink:href="https://rennesens.en.ecplaza.net/products/cardiodetect-med-fabp-rapid-test_261655">https://rennesens.en.ecplaza.net/products/cardiodetect-med-fabp-rapid-test_261655</ext-link>
</td><td align="left" rowspan="1" colspan="1">Fatty&#x02010;Acid&#x02010;Binding Proteins</td><td align="left" rowspan="1" colspan="1">N/A</td></tr><tr><td align="left" rowspan="1" colspan="1">Roche CARDIAC&#x000ae; POC Troponin T (Troponin T assay) on the cobas h 232 POC system</td><td align="left" rowspan="1" colspan="1">3</td><td align="left" rowspan="1" colspan="1">Roche</td><td align="left" rowspan="1" colspan="1">
<ext-link ext-link-type="uri" xlink:href="http://www.cobas.com/home/product/point-of-care-testing/cobas-h-232.html">http://www.cobas.com/home/product/point-of-care-testing/cobas-h-232.html</ext-link>
</td><td align="left" rowspan="1" colspan="1">Troponin T</td><td align="left" rowspan="1" colspan="1">CK&#x02010;MB, D&#x02010;Dimer, Myoglobin, NT&#x02010;proBNP</td></tr></tbody></table><permissions><copyright-holder>John Wiley &#x00026; Sons, Ltd</copyright-holder><license><license-p>This article is being made freely available through PubMed Central as part of the COVID-19 public health emergency response. It can be used for unrestricted research re-use and analysis in any form or by any means with acknowledgement of the original source, for the duration of the public health emergency.</license-p></license></permissions></table-wrap></sec></app></app-group></back></article>